Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Patrick Burnett Sells 684 Shares of Stock

Key Points

• Insider sale: Patrick Burnett sold 684 shares at an average price of $23.61 (total ~$16,149) under a pre‑arranged Rule 10b5‑1 plan to cover tax withholding from vested awards and still directly owns 120,466 shares (a 0.56% drop).
• Q1 product momentum: ZORYVE net product revenue was $105.4M (≈+65% YoY), beating consensus and supporting positive operating cash flow, although the company missed on EPS (loss of $0.09 vs. $0.02 expected).
• Pipeline and sentiment: Arcutis submitted an sNDA for infants, completed pediatric trial enrollment and started first‑in‑human ARQ‑234 studies, while analysts maintain a “Moderate Buy” consensus with a ~$34 average price target and several firms raising their targets.

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) insider Patrick Burnett sold 684 shares of the firm's stock in a transaction on Monday, May 4th. The stock was sold at an average price of $23.61, for a total value of $16,149.24. Following the completion of the transaction, the insider directly owned 120,466 shares in the company, valued at approximately $2,844,202.26. This represents a 0.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Patrick Burnett also recently made the following trade(s):

• On Monday, March 2nd, Patrick Burnett sold 6,287 shares of Arcutis Biotherapeutics stock. The shares were sold at an average price of $25.18, for a total value of $158,306.66.

Arcutis Biotherapeutics Stock Performance

ARQT traded up $0.75 during midday trading on Wednesday, reaching $24.17. The company had a trading volume of 1,381,968 shares, compared to its average volume of 1,329,167. The business has a 50-day moving average of $23.82 and a two-hundred day moving average of $25.75. The company has a quick ratio of 2.99, a current ratio of 3.17 and a debt-to-equity ratio of 0.57. Arcutis Biotherapeutics, Inc. has a 1 year low of $12.42 and a 1 year high of $31.77. The company has a market cap of $3.02 billion, a P/E ratio of -172.63 and a beta of 1.58.

Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.07). The company had revenue of $105.40 million for the quarter, compared to analysts' expectations of $103.68 million. Arcutis Biotherapeutics had a negative net margin of 4.29% and a negative return on equity of 10.26%. As a group, equities research analysts predict that Arcutis Biotherapeutics, Inc. will post 0.18 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on ARQT shares. Needham & Company LLC upped their price target on shares of Arcutis Biotherapeutics from $31.00 to $36.00 and gave the stock a "buy" rating in a research report on Thursday, February 26th. Mizuho lowered their target price on shares of Arcutis Biotherapeutics from $37.00 to $35.00 and set an "outperform" rating on the stock in a research note on Monday, March 2nd. HC Wainwright upped their target price on shares of Arcutis Biotherapeutics from $30.00 to $34.00 and gave the stock a "buy" rating in a report on Thursday, February 26th. TD Cowen increased their target price on Arcutis Biotherapeutics from $30.00 to $35.00 and gave the stock a "buy" rating in a research report on Thursday, February 26th. Finally, Wall Street Zen downgraded Arcutis Biotherapeutics from a "strong-buy" rating to a "buy" rating in a research note on Saturday, February 14th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $34.00.

Hedge Funds Weigh In On Arcutis Biotherapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Suvretta Capital Management LLC boosted its position in shares of Arcutis Biotherapeutics by 14.2% during the 4th quarter. Suvretta Capital Management LLC now owns 11,964,000 shares of the company's stock valued at $347,435,000 after acquiring an additional 1,486,000 shares during the last quarter. Jennison Associates LLC raised its holdings in shares of Arcutis Biotherapeutics by 10.3% in the third quarter. Jennison Associates LLC now owns 12,254,119 shares of the company's stock worth $230,990,000 after buying an additional 1,144,714 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in shares of Arcutis Biotherapeutics by 1,228.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,166,348 shares of the company's stock valued at $33,872,000 after purchasing an additional 1,078,546 shares during the period. Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of Arcutis Biotherapeutics in the fourth quarter worth about $26,136,000. Finally, State Street Corp grew its holdings in shares of Arcutis Biotherapeutics by 18.2% in the fourth quarter. State Street Corp now owns 5,488,301 shares of the company's stock worth $159,380,000 after purchasing an additional 846,986 shares during the last quarter.

Key Stories Impacting Arcutis Biotherapeutics

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Q1 product momentum — ZORYVE net product revenue was $105.4M, up ~65% year‑over‑year and above consensus revenue; company said it maintained positive operating cash flow and highlighted continued branded non‑steroidal share gains. Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Regulatory and pipeline progress — submitted an sNDA to expand ZORYVE for infants (3–24 months), completed enrollment in the ZORYVE foam pediatric MUSE trial, and started first‑in‑human studies of ARQ‑234. These catalysts support longer‑term growth expectations. Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Commercial build — expanded the dermatology sales force and is building a primary care/pediatrics organization, which could broaden ZORYVE adoption. Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Analyst stance — broker consensus remains a “Moderate Buy,” supporting investor sentiment around upside to the current share price. Arcutis Receives Consensus Recommendation of "Moderate Buy"
• Neutral Sentiment: Insider sales disclosed — several executives and a director sold shares recently (executed under pre‑arranged Rule 10b5‑1 plans and largely to cover taxes on vested awards), which is typical after vesting and less likely to signal negative insider sentiment. Representative SEC filing: Todd Watanabe Form 4

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company's research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.